Serologic assessment of type 1 and type 2 immunity in healthy Japanese adults

Cancer Epidemiology Biomarkers and Prevention

Volumn 13, Issue 8, 2004, Pages 1385-1391

  Birmann, Brenda M ^a   Mueller, Nancy ^a   Okayama, Akihiko ^b   Hsieh, Chung Cheng ^a,c   Tachibana, Nobuyoshi ^d   Tsubouchi, Hirohito ^b   Lennette, Evelyne T ^e   Harn, Donald ^a   Stuver, Sherri ^a,f  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d Miyazaki Prefectural Nursing University   (Japan)

^e Nectandra Institute   (Costa Rica)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD23 ANTIGEN; CD30 ANTIGEN; IMMUNOGLOBULIN E; TUBERCULIN;

ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; HUMAN; HUMAN EXPERIMENT; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOREACTIVITY; JAPAN; NORMAL HUMAN; PRIORITY JOURNAL; TUBERCULIN TEST;

ADULT; AGE DISTRIBUTION; BIOLOGICAL MARKERS; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HTLV-I ANTIBODIES; HTLV-I INFECTIONS; HUMANS; IMMUNITY, CELLULAR; INCIDENCE; JAPAN; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; RURAL POPULATION; SEROLOGIC TESTS; SEX DISTRIBUTION; TUBERCULIN TEST;

EID: 4043126291     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Lucey DR, Clerici M, Shearer GM, Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996;9:532-62.
2. H2 cells. J Clin Immunol 1995;15:121-9.
3. Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 2000;85:9-21.
4. Bienvenu JAD, Monneret G, Gutowski MC, Fabien N. Cytokine assays in human sera and tissues. Toxicology 1998;129:55-61.
5. Whiteside TL. Cytokine measurements and interpretation of cytokine assays in human disease. J Clin Immunol 1994;14:327-39.
6. Henle W, Henle G. Epstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res 1981;41:4222-5.
7. Delespesse G, Suter U, Mossalayi D, et al. Expression, structure and function of the CD23 antigen. Adv Immunol 1991;49:149-91.
8. Gordon J. CD23 and B cell activation. Clin Exp Allergy 1992;22:199-204.
9. Bansal AS, Ollier W, Marsh MN, Pumphrey RSH, Wilson PB. Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity. Immunology 1993;79:285-9.
10. Smith C, Davis T, Anderson D, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990;248:1019-23.
11. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin's and Reed-Sternberg cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982;299:65-7.
12. Stein H, Maon DY, Gerdes J, et al. The expression of the Hodgkin's disease-associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that the Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-58.
13. Pizzolo G, Romagnani S. CD30 molecule (Ki-1 Ag): more than just a marker of CD30+ lymphoma. Haematologica 1995;80:357-66.
14. D'Elios MM, Romagnani P, Scaletti C, et al. In vivo CD30 expression in human diseases with predominant activation of Th2-like cells. J Leuk Biol 1997;61:539-44.
15. Hisada M, Stuver SO, Okayama A, Mueller NE. Gender differences in skin reactivity to purified protein derivative among carriers of HTLV-I in Japan. J AIDS J Acquir Immune Defic Syndr 1999;22:302-7.
16. Mueller N, Okayama A, Stuver S, Tachibana N. Findings from the Miyazaki Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S2-7.
17. Okayama A, Stuver S, Iga M, et al. Sequential change of virus markers in seroconverters with community-acquired infection of human T-lymphotropic virus type I. J Infect Dis 2001;183:1031-7.
18. Boschi-Pinto C, Stuver S, Okayama A, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000;181:35-41.
19. Hisada M, Shima T, Okayama A, Mueller N, Tsubouchi H, Stuver S. Suppression of skin reactivity to purified protein derivative by hepatitis C virus among HTLV-I carriers in Japan. J Aquir Immune Defic Syndr Hum Retrovirol 1998;19:421-5.
20. Tachibana N, Okayama A, Ishizaki J, et al. Suppression of tuberculin skin reaction in healthy HTLV-1 carriers from Japan. Int J Cancer 1988;42:829-31.
21. Murai K, Tachibana N, Shioiri S, et al. Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers. J AIDS 1990;3:1006-9.
22. Henle W, Henle G, Horwitz CA. Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol 1974;5:551-65.
23. Lennette ET, Rymo L, Yadav M, et al. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur J Cancer 1993;29A:1584-9.
24. Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven Publishers; 1998.
25. Henle W, Henle G, Andersson J, et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci USA 1987;84:570-4.
26. Matricardi PM, Yazdanbakhsh M. Mycobacteria and atopy, 6 years later: a fascinating, still unfinished, business. Clin Exp Allergy 2003;33:717-20.
27. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997;275:77-9.
28. Schönermarck U, Csernok E, Trabandt A, Hansen H, Gross WL. Circulating cytokines and soluble CD23, CD26 and CD30 in ANCA-associated vasculitides. Clin Exp Rheumatol 2000;18:457-63.
29. Yawetz S, Cumberland WG, van der Meyden M, Martínez-Maza O. Elevated serum levels of soluble CD23 (sCD23) precede the appearance of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma. Blood 1995;85:1843-9.
30. Wilhelm D, Klouche M, Görg S, Kirchner H. Expression of sCD23 in atopic and nonatopic blood donors: correlation with age, total serum IgE, and allergic symptoms. Allergy 1994;49:521-5.
31. Schroeder JR, Saah AJ, Hoover DR, et al. Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 1999;8:979-84.
32. Latza U, Davis S, Wilhelm D, McKnight B, Seyfarth M, Stein H. Soluble cytokine receptor CD30 in atopic disorders: a case-control study. Clin Exp Allergy 1999;29:97-104.
33. Katoh N, Hirano S, Suehiro M, et al. Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. Clin Exp Immunol 2000;121:187-92.